• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

D 组眼经化学减瘤和低剂量 IMRT 挽救治疗后长期视力结局的预测因素:洛杉矶儿童医院的经验。

Factors predictive of long-term visual outcomes of Group D eyes treated with chemoreduction and low-dose IMRT salvage: the Children's Hospital Los Angeles experience.

机构信息

The Vision Center at Children's Hospital Los Angeles, Los Angeles, California, USA.

The Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California, USA.

出版信息

Br J Ophthalmol. 2014 Aug;98(8):1061-5. doi: 10.1136/bjophthalmol-2013-304411. Epub 2014 Mar 26.

DOI:10.1136/bjophthalmol-2013-304411
PMID:24671926
Abstract

AIM

To evaluate clinical factors predictive of visual outcomes in Group D retinoblastoma eyes.

METHODS

Retrospective chart review of patients with Group D retinoblastoma from January 2000 to December 2009. All patients were treated with systemic chemoreduction and external beam radiation as salvage therapy when indicated. Primary outcome measure was visual acuity. Clinical factors evaluated include quadrants of subretinal fluid, extent of vitreous seeding, involvement of more/less than 50% of the macula, endophytic/exophytic tumour classification, and presence of tumour behind the lens at diagnosis.

RESULTS

Fifty-two Group D eyes of 41 patients were included; 10 eyes with visual acuity better than 20/80, 32 eyes with vision worse than 20/100 and 10 eyes with indeterminate vision (fix and follow). Complete retinal detachment (p=0.002), involvement of >50% of the macula (p=0.01), and seeding >3 quadrants (p=0.05) were associated with worse visual outcome. Average follow-up was 50.0 months (range: 10-118 months).

CONCLUSIONS

At presentation, it is difficult to predict which Group D eyes will be salvaged with useful vision following systemic chemotherapy. The presence of complete retinal detachment, macular involvement and extensive seeding on presentation were factors associated with a worse visual prognosis in this study. These findings can guide the ophthalmologist in clinical decision making, as well as in counselling parents.

摘要

目的

评估 D 组视网膜母细胞瘤眼的预测视力结果的临床因素。

方法

回顾性分析 2000 年 1 月至 2009 年 12 月期间 D 组视网膜母细胞瘤患者的病历。所有患者均接受全身化疗和外照射治疗作为挽救治疗,如果需要的话。主要观察指标是视力。评估的临床因素包括视网膜下液的象限、玻璃体内播种的程度、是否累及黄斑 50%以上、内/外生肿瘤分类以及诊断时晶状体后肿瘤的存在。

结果

41 例患者的 52 只 D 组眼,其中 10 只眼视力优于 20/80,32 只眼视力差于 20/100,10 只眼视力不确定(固定和随访)。完全视网膜脱离(p=0.002)、黄斑受累>50%(p=0.01)和播种超过 3 个象限(p=0.05)与视力预后较差相关。平均随访时间为 50.0 个月(范围:10-118 个月)。

结论

在出现时,很难预测哪些 D 组眼在全身化疗后能够挽救有用的视力。本研究中,完全视网膜脱离、黄斑受累和播种广泛是视力预后较差的相关因素。这些发现可以指导眼科医生做出临床决策,并为家长提供咨询。

相似文献

1
Factors predictive of long-term visual outcomes of Group D eyes treated with chemoreduction and low-dose IMRT salvage: the Children's Hospital Los Angeles experience.D 组眼经化学减瘤和低剂量 IMRT 挽救治疗后长期视力结局的预测因素:洛杉矶儿童医院的经验。
Br J Ophthalmol. 2014 Aug;98(8):1061-5. doi: 10.1136/bjophthalmol-2013-304411. Epub 2014 Mar 26.
2
Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage.化疗降低风险联合低剂量调强放疗挽救治疗后双眼视网膜母细胞瘤 D 组眼的长期疗效
Pediatr Blood Cancer. 2013 Apr;60(4):688-93. doi: 10.1002/pbc.24303. Epub 2012 Sep 19.
3
Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.E 组视网膜母细胞瘤的化学减容:76 只眼单纯化学减容与化学减容加低剂量外照射放疗的比较
Ophthalmology. 2009 Mar;116(3):544-551.e1. doi: 10.1016/j.ophtha.2008.10.014. Epub 2009 Jan 20.
4
Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.视网膜母细胞瘤中化学减灭术失败的原因及导致最终采用外照射放疗和眼球摘除术治疗的相关因素分析。
Ophthalmology. 2004 Oct;111(10):1917-24. doi: 10.1016/j.ophtha.2004.04.016.
5
Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.采用化学减容法治疗的黄斑区视网膜母细胞瘤:68例肿瘤接受或未接受辅助热疗的肿瘤控制情况分析
Arch Ophthalmol. 2005 Jun;123(6):765-73. doi: 10.1001/archopht.123.6.765.
6
Salvage external beam radiotherapy after failed primary chemotherapy for bilateral retinoblastoma: rate of eye and vision preservation.双侧视网膜母细胞瘤初次化疗失败后挽救性外照射放疗:眼球和视力保留率
Br J Ophthalmol. 2009 Jul;93(7):891-4. doi: 10.1136/bjo.2007.129981. Epub 2009 Mar 26.
7
Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.黄斑区视网膜母细胞瘤:化疗联合重复黄斑中心凹激光消融治疗后眼部肿瘤控制、局部并发症及视力预后评估
Ophthalmology. 2007 Jan;114(1):162-9. doi: 10.1016/j.ophtha.2006.06.042. Epub 2006 Oct 27.
8
Management and outcome of retinoblastoma with vitreous seeds.玻璃体内播散性视网膜母细胞瘤的处理和结局。
Ophthalmology. 2014 Feb;121(2):517-24. doi: 10.1016/j.ophtha.2013.09.011. Epub 2013 Oct 25.
9
Long-term visual outcome following chemoreduction for retinoblastoma.视网膜母细胞瘤化疗减积后的长期视觉预后
Arch Ophthalmol. 2005 Nov;123(11):1525-30. doi: 10.1001/archopht.123.11.1525.
10
Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation.全身化学减瘤治疗与初次眼球摘除术治疗晚期视网膜母细胞瘤眼的转移和眼眶复发风险。
Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26270. Epub 2016 Nov 5.

引用本文的文献

1
A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231).一项针对 C 组和 D 组眼内视网膜母细胞瘤的全身和经Tenon 下化疗的单臂研究:儿童肿瘤学组研究(ARET 0231)。
Pediatr Blood Cancer. 2020 Sep;67(9):e28502. doi: 10.1002/pbc.28502. Epub 2020 Jun 26.
2
Association of electroretinography with visual outcomes after ophthalmic artery chemosurgery for retinoblastoma in ICRb D and E eyes.眼动脉化疗治疗 ICRb D 和 E 眼视网膜母细胞瘤后的视网膜电图与视力结局的关系。
PLoS One. 2019 Jan 16;14(1):e0210647. doi: 10.1371/journal.pone.0210647. eCollection 2019.
3
Optic Nerve Obscuration in Retinoblastoma: A Risk Factor for Optic Nerve Invasion?
视网膜母细胞瘤中的视神经遮挡:视神经侵犯的一个危险因素?
Ocul Oncol Pathol. 2017 Nov;3(4):283-291. doi: 10.1159/000464468. Epub 2017 Apr 7.
4
Potential of Aqueous Humor as a Surrogate Tumor Biopsy for Retinoblastoma.房水作为视网膜母细胞瘤替代肿瘤活检的潜力。
JAMA Ophthalmol. 2017 Nov 1;135(11):1221-1230. doi: 10.1001/jamaophthalmol.2017.4097.
5
Low-Dose Chemoreduction for Infants Diagnosed with Retinoblastoma before 6 Months of Age.6个月龄前诊断为视网膜母细胞瘤的婴儿的低剂量化疗减瘤法
Ocul Oncol Pathol. 2015 Feb;1(2):103-10. doi: 10.1159/000370215. Epub 2015 Jan 16.
6
Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors.靶向Survivin增强视网膜母细胞瘤细胞和原位肿瘤的化学敏感性。
PLoS One. 2016 Apr 6;11(4):e0153011. doi: 10.1371/journal.pone.0153011. eCollection 2016.
7
Long-term visual outcomes in intraocular retinoblastoma with eye preservation.眼内视网膜母细胞瘤保眼治疗后的长期视觉预后
Clin Transl Oncol. 2016 Oct;18(10):1034-8. doi: 10.1007/s12094-016-1482-4. Epub 2016 Jan 19.